Pioneering Non-Viral Gene Delivery
At AAVINUE, we are driven by a vision to revolutionize gene therapy for debilitating diseases using our proprietary Mini-nucleosome non-viral delivery technology. Our work is dedicated to overcoming the challenges of viral vectors and LNPs to enable transformative therapies for conditions like ALS, Stargardt's, Alzheimer’s Disease, and other genetic diseases.
Patient Focused
Patient first mentality drives our entire drug development process.
Cutting-Edge Technology
Leader in non-viral gene Delivery and Cargo technologies.
Robust Platforms
Customizable for targeted delivery of DNA/RNA to treat diverse diseases
Designed for Success
Highly accessible to patients via friendly economics
Collaborative Innovation and Approach
Backed by a team of seasoned experts in neuroscience, ophthalmology gene therapy, and biotech entrepreneurship, AAVINUE has developed scalable gene therapy solutions already for high unmet need diseases. Our approach is grounded in rigorous science and strengthened through collaborations with world-class academic investigators.
Nature-Inspired Breakthroughs
With a robust intellectual property portfolio and long patent life, AAVINUE is positioned to lead the next wave of breakthroughs in non-viral gene therapy.
Our Pipeline
Transforming the Future
Join us in transforming the future of ophthalmic and neurodegenerative disease treatment—without the virus. Reach out to us for more information.